Phase II Study of Subcutaneous Erythropoietin for Treatment of Myelodysplastic Syndromes (FAB Type I and II): A Trial of the Phase l/ll Study Group of the Association for Medical Oncology of the German Cancer Society

G. Hartung,A. Weigold,S. Ohl,U. Essers,M.E. Heim,D. Fritze,M. Baldus,D. Hoelzer,K. Bremer,O. Quarder,Lutz Edler,W. Queißer

Phase II Study of Subcutaneous Erythropoietin for Treatment of Myelodysplastic Syndromes (FAB Type I and II): A Trial of the Phase l/ll Study Group of the Association for Medical Oncology of the German Cancer Society

1995

G. Hartung
A. Weigold
S. Ohl
U. Essers
M.E. Heim
D. Fritze
M. Baldus
D. Hoelzer
K. Bremer
O. Quarder
Lutz Edler
W. Queißer

Background : Anemia in patients with myelodysplastic syndromes (MDS) is usually put down to ineffective erythropoiesis, although the contributory role of other mechanisms has not bee

Keywords:

Cancer
Refractory anemia with ring sideroblasts
Erythropoietin
Phases of clinical research
Anemia
Intensive care medicine
Medicine
Myelodysplastic syndromes
Ineffective erythropoiesis
Oncology
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations